arrow
A

Aki Sakurai

pennsylvania commonwealth system of higher education (pcshe)
H指数:20
被引数:1,411

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Difficult-to-treat resistance (DTR), treatment, and outcomes of carbapenem-resistant Enterobacterales infections in the setting of IMP-type carbapenemase predominance in Japan

难治性耐药(DTR)、治疗及结果:日本IMP型碳青霉烯酶占主导的碳青霉烯耐药肠杆菌科细菌感染

2026-06-020
PRE
Features of Carbapenem-resistant Gram-negative Bacterial Infections in Japan Based on the Setting of Onset

基于发病场所的日本碳青霉烯耐药革兰氏阴性菌感染特征

2025-10-010
OAAI
Molecular epidemiology and patient outcome of carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii in Japan: a multicenter study from MultiDrug-Resistant organisms clinical research network
2025-03-060
OAAI
A predictive model for HIV-related lymphoma
AIDS
IF3.1
2024-06-240
OAAI
Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA
2023-01-022
OAAI
Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis

哌拉西林-他唑巴坦与碳青霉烯类药物治疗低OXA-1地区产超广谱 β-内酰胺酶大肠埃希菌菌血症疗效的初步分析

2022-08-318
OAAI
In Vitro Activity and Clinical Efficacy of Faropenem against Third-Generation Cephalosporin-Resistant Escherichia coli and Klebsiella pneumoniae

法罗培南对第三代头孢菌素耐药的大肠埃希菌和肺炎克雷伯菌的体外活性及临床疗效

2022-06-211
OA